Levetiracetam Solution
Product Images NDC 17856-0574

7 FDA label images from Atlantic Biologicals Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 17856-0574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

17856 0574 01

17856 0574 01
Levetiracetam 500 mg/5 mL oral solution unit dose label showing dosage form and strength. The label includes storage instructions at 20°-25°C and a warning to keep medication out of children's reach. It indicates a quantity of 72 cups, repackaged by Unit Dose Solutions, and distributed by Atlantic Biologicals Corp. Contact and reorder information is also displayed.*
FDA Label Image

Image Description (Figure)

Image Description (Figure)
A vertical bar chart showing patient percentage response comparing placebo and two dosages of Levetiracetam (1000 mg/day and 3000 mg/day). The y-axis represents the percentage of patients from 0% to 45%, and the x-axis shows three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The chart includes sample sizes for each group.*
FDA Label Image

Image Description (Figure1)

Image Description (Figure1)
Bar graph comparing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, ranging from 0% to 45%, with respective values approximately 6.3%, 20.8%, and 35.2% for each group.*
FDA Label Image

Image Description (Figure2)

Image Description (Figure2)
Bar chart comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The placebo group (N=104) shows approximately 14.4% of patients, while the Levetiracetam group (N=180) shows about 39.4% of patients. The chart illustrates efficacy comparison between these groups.*
FDA Label Image

Image Description (Figure3)

Image Description (Figure3)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=97) shows 19.6%, while the Levetiracetam group (N=101) shows 44.6%. The vertical axis represents the percentage of patients from 0% to 45%.*
FDA Label Image

Image Description (Figure4)

Image Description (Figure4)
A bar chart comparing the percentage of responders between two groups: Placebo (N=84) with 45.2% responders and Levetiracetam (N=79) with 72.2% responders. The chart visually shows a higher response rate for Levetiracetam.*
FDA Label Image

Image Description (Structure)

Image Description (Structure)
Chemical structure diagram of Levetiracetam, showing its molecular formula with a pyrrolidone ring attached to an ethyl side chain and an acetamide group, as represented in this structural formula image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.